Anti-angiogenic therapy in renal cell cancer.


Journal Article (Review)

Angiogenesis is an important hallmark of RCC, reflected in the natural history, Histology, genetics and now therapeutics of this disease. Clearly, the pro-angiogenic growth factor VEGF is a functional drug target in RCC and many strategies to inhibit this biology have shown clinical benefit. Multi-targeted TKI that inhibit VEGFRs have been approved by the FDA as standard treatment for advanced RCC. Pharmacodynamyc studies suggest that these agents and others also have anti-angiogenic effects. Currently, studies combining VEGFR-targeted strategies with other anti-angiogenic agents, including anti-VEGF antibodies, IFN or mTOR inhibitors, are underway. However, to what extent the clinical benefit of anti-angiogenic strategies in RCC can be built upon is unknown.

Full Text

Duke Authors

Cited Authors

  • Srinivasan, R; Armstrong, AJ; Dahut, W; George, DJ

Published Date

  • May 2007

Published In

Volume / Issue

  • 99 / 5 Pt B

Start / End Page

  • 1296 - 1300

PubMed ID

  • 17441927

Pubmed Central ID

  • 17441927

International Standard Serial Number (ISSN)

  • 1464-4096

Digital Object Identifier (DOI)

  • 10.1111/j.1464-410X.2007.06834.x


  • eng

Conference Location

  • England